[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Massachusetts Institute of Technology\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":313},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,46,74,97,127,150,173,198,223,249,268,290],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100632056","transcranial-ultrasonic-neuromodulation-of-primary-visual-cortex-and-primary-auditory-cortex-in-humans-100632056",false,"NCT07508722","Transcranial Ultrasonic Neuromodulation of Primary Visual Cortex and Primary Auditory Cortex in Humans","The inclusion criteria for this study are as follows:\n\n1. Healthy male and female adults aged 21-55.\n2. No contraindications to magnetic resonance imaging (MRI) scans, such as claustrophobia.\n\nThe exclusion criteria for this study are as follows:\n\n1. History of major medical, neurological (including peripheral nerve disease) or psychiatric illness.\n2. History of vsacular conditions, predisposition to hemorrhage, or blood thinner medications\n3. History of head trauma with loss of consciousness.\n4. Use of sedatives, analgesics and agents that affect brain function.\n5. Contraindications for exposure to the high magnetic field of MRI imaging\n6. History of skin irritation from acoustic coupling materials such as a water-based gel and polyvinyl alcohol (PVA; a common household plastic bag material).\n7. Vulnerable subpopulations (pregnant women, children, institutionalized individuals).\n8. Use of excessive alcohol (e.g., no more than one can of beer or glass of wine) or strenuous exercise (e.g., no more than daily routine) on the day of the visit",true,"ALL","21 Years","55 Years",{"count":20,"type":21},20,"ESTIMATED","INTERVENTIONAL",[24],"NA","There are a number of disorders of the brain that have limited treatment options, such as chronic pain, addiction, and major depression. A new technology has emerged in the last decade known as transcranial focused ultrasound, which can deliver focused acoustic signals through the skull to modulate brain activity over a small region, including structures deep in the brain. This has resulted in many ongoing clinical trials for various disorders, but there is still a lack of understanding of the optimal sonication parameters for increasing versus decreasing brain activity. The investigators aim to address this open question by sonicating the primary visual cortex and primary auditory cortex in human with a range of sonication parameters. These brain structures were chosen to target because they are expected to elicit perceptual responses in the subject (i.e., the subject will report visual and auditory perception during sonication), allowing the experimenters to infer directly the extent to which neural signals can propagate through the visual and auditory systems in a way that is sufficient to produce conscious perception. Such findings have applications not only in clinical treatments, but also in the fundamental science of the neural basis of sensory perception. Previous work has shown that sonicating the visual cortex in humans can elicit visual perception, but the ultrasonic system in prior work did not have the focusing capabilities that will be employed in this study. At the end of this study, the investigators will have determined the optimal sonication parameters that can elicit neural responses over a small volume over sensory cortex, which can be inferred from visual percepts being localized in space (e.g., a bright spot as opposed to a diffuse light), and auditory percepts that sound like pure tones rather than a broad set of frequencies (e.g., sounding like white noise or static).",[27,28],"Healthy Volunteers","no Condition, Basic Science",[30,31,32],"Transcranial Focused Ultrasound","Non-invasive Brain Stimulation","Ultrasound Neuromodulation","NOT_YET_RECRUITING","2026-06-26",{"date":36,"type":37},"2026-06-29","ACTUAL",{"date":39,"type":21},"2026-10-01",{"date":41,"type":21},"2027-06-01",{"name":43,"class":44},"Massachusetts Institute of Technology","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":45},"100643041","evaluation-of-a-powered-ankle-prosthesis-capable-of-bidirectional-control-via-neural-recording-and-cutaneous-stimulation-in-free-space-and-walking-tasks-100643041","NCT07645729","Evaluation of a Powered Ankle Prosthesis Capable of Bidirectional Control Via Neural Recording and Cutaneous Stimulation in Free-Space and Walking Tasks","Inclusion Criteria:\n\n* Male or Female age 18-70. The patient must have a unilateral transtibial amputation . The patient must have the ability to ambulate at variable cadence (an expected lower extremity prosthesis functional level of K3 or above).\n\nThe patient must have adequate socket to support the device.\n\nExclusion Criteria:\n\n* Women who are pregnant. Severe co morbidity, atypical skeletal anatomy, or poor general physical\u002Fmental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectancy, vulnerable patient population, BMI \\>40, etc.).","18 Years","70 Years",{"count":55,"type":21},10,[24],"The purpose of this study is to evaluate the performance of a powered ankle prosthesis capable of bidirectional control via neural recording and cutaneous stimulation, during free-space and walking tasks. This research aims to assess the sense of embodiment with the device, gait symmetry, and stability of a person with lower-extremity amputation walking with a powered ankle and their prescribed prosthesis. Findings from this study will inform future developments in bionic ankle design with optimal integration with the human body, with the goal of improving prosthetic integration into daily life.",[59],"Amputation",[61,62,63,64],"prosthesis","neuroprosthesis","osseointegration","amputation","RECRUITING","2026-06-11",{"date":68,"type":37},"2026-06-12",{"date":70,"type":37},"2025-10-21",{"date":72,"type":21},"2031-09-30",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":83,"briefSummary":84,"conditions":85,"keywords":87,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":45},"100641192","study-of-wearable-interventions-for-improving-mobility-of-individuals-with-knee-osteoarthritis-100641192","NCT07652437","Study of Wearable Interventions for Improving Mobility of Individuals With Knee Osteoarthritis","Inclusion Criteria:\n\n* Any gender\n* 21+ years of age\n* Doctor-diagnosed tibiofemoral knee osteoarthritis\n* Self-report knee pain or stiffness on most days of the past month\n* Self-report of difficulty walking due to at least one knee\n* Self-report of restricted walking behavior (not engaging in 150 minutes of moderate walking a week) due to at least in part one knee\n* Able to walk one block without the use of an assistive device (e.g. a cane or walker)\n* Able to engage in a walking activity program with the wearable intervention for approximately 30 minutes using standing or sitting rests as needed\n\nExclusion Criteria:\n\n* Unable to walk at least 10 minutes in the community due to an existing cardiovascular, cardiopulmonary, musculoskeletal, or neurological condition\n* Planning knee, hip, ankle or back surgery within the next 6-months\n* Ankle or hip osteoarthritis\n* Inflammatory arthritis (e.g., rheumatoid arthritis, psoriatic arthritis, scleroderma, Lymes Disease, Lupus)\n* Bilateral total knee replacements\n* Use of an assistive device (e.g., walker or cane) in home or in the community\n* Self-reported fall within the past 6-months that resulted in limitations in daily activities\n* Lower extremity\u002Ffoot peripheral neuropathy or other sensory disorders\n* Diagnosed with vestibular or other balance disorder that impact walking\n* Open wounds or active skin irritation on the leg shank\n* Open wounds or active ulcers of either feet\n* Unstable cardiovascular disease\n* Unstable respiratory disease\n* History of past or current deep vein thrombosis\n* Active back pain that limits walking\n* Use of supplemental oxygen to walk","100 Years",{"count":82,"type":21},9,[24],"Knee osteoarthritis (OA) affects an estimated 654 million people over age 40 world-wide. In the United States, approximately 16% of adults over the age of 40 have knee OA. Pain, activity limitations and disability are common symptoms. Exercise is widely recommended as a non-invasive, first line strategy for people with knee OA. Yet, less than 1\u002F3 of adults with knee OA meet recommended levels of physical activity, and rates are even lower among people who are overweight. Furthermore, adherence to evidence-based structured programs is poor once the therapeutic support is removed. End stage disease is treated by total joint replacement. Under-active people with knee OA would benefit from general walking activity, even if joint replacement surgery is expected; however, walking is difficult and motivation is low. Thus, people with knee OA encounter a difficult paradox: exercise could help decrease pain and improve function but doing so can be difficult and may not always be possible. There is a tremendous need to address this situation. This is a small device-feasibility study evaluating the Dephy ExoBoot, a wearable powered exoskeleton, in individuals with knee OA. The study assesses whether the device can reliably deliver positive assistance during walking and is tolerated across walking tasks. Additional measures, including changes in knee loading and walking speed with versus without the device, are also collected.",[86],"Knee Osteoarthristis",[88,89],"knee osteoarthritis","exoskeleton",{"date":91,"type":37},"2026-06-17",{"date":93,"type":37},"2025-12-15",{"date":95,"type":21},"2029-07-01",{"name":43,"class":44},{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":16,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":108,"briefSummary":109,"conditions":110,"keywords":112,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":45},"100459920","high-frequency-light-sound-and-tactile-stimulation-to-improve-motor-and-cognitive-deficits-in-parkinsons-disease-100459920","NCT05268887","High Frequency Light, Sound, and Tactile Stimulation to Improve Motor and Cognitive Deficits in Parkinson's Disease","Acute Treatment of Parkinson's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\n* Subject has Idiopathic PD defined by the cardinal sign, bradykinesia, plus the presence of at least 1 of the following: resting tremor or rigidity and without any other known or suspected cause of Parkinsonism (according to Movement disorder society (MDS) clinical diagnostic criteria for Parkinson's disease confirmed by a fellowship trained movements disorder specialist\n* Subject is Hoehn \\& Yahr stage 2 to 3\n* Subject has a Montreal Cognitive Assessment (MOCA) score ≥26.\n* Subject is \\> 45 and \\\u003C90 years of age.\n* proficient in speaking, reading, and understanding English\n* capable of providing informed written consent\n* Subject is on a stable dose (at least 1 month prior to baseline visit) of antiparkinsonian agents and willing to remain on this dose for the duration of the study. If on a cholinesterase inhibitor, a stable dose without changes for 1 month is required.\n* Subject has undergone a brain CT or MRI prior to rule out underlying structural lesions\n\nExclusion criteria:\n\n* Subject has atypical Parkinson's syndrome(s) due to drugs, metabolic neurogenetic disorders (e.g., Wilson's Disease), encephalitis, cerebrovascular disease, or degenerative disease (e.g., Progressive Supranuclear Palsy, Multiple System Atrophy, Corticobasal Degeneration, Lewy Body dementia)\n* history of any psychiatric illness that would pose a safety risk\n* diagnosis of dementia or other neurological conditions\n* currently taking sedative medications that are clinically contraindicated\n* has undergone recent change (\\\u003C1 month) in medication\n* recent drug or alcohol abuse or dependence\n* laboratory results the would pose safety risk\n* concurrently or has participated in other clinical trial investigation within 3 months\n* pregnant\n* no healthcare\n* history of epilepsy, stroke, or seizure in past 24 months\n* diagnosis of migraines\n* have certain implantable medical devices\n* contraindications for MRI\n* life expectancy of less than 2 years","45 Years","90 Years",{"count":107,"type":21},40,[24],"Parkinson's disease (PD) impacts different types of neural oscillations in the brain, including beta (13-30Hz) and gamma oscillations (30-80Hz), which contributes to PD's cardinal symptoms of resting tremor, rigidity, bradykinesia (slowness of movement), and gait instability. The investigators' lab has developed a non-invasive method of increasing gamma power in the brain using Gamma Entrainment Using Sensory Stimulation (GENUS) through light, sound, and tactile stimulation devices. For this study, 40 participants with mild Parkinson's disease will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) before, during, and after light, sound, and tactile stimulation to determine the safety, feasibility, and optimization of GENUS as a potential therapy in the PD population.",[111],"Parkinson Disease",[113,114,115,116,117,118],"Parkinson's Disease","Motor Impairment","Non-Invasive Sensory Stimulation","Light and Sound Stimulation","Tactile Stimulation","Gamma","2026-03-30",{"date":121,"type":37},"2026-03-31",{"date":123,"type":37},"2022-02-09",{"date":125,"type":21},"2027-11",{"name":43,"class":44},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":15,"sex":16,"minAge":134,"maxAge":135,"enrollmentInfo":136,"targetDuration":4,"studyType":22,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":45},"100454395","gamma-frequency-stimulation-in-individuals-with-down-syndrome-100454395","NCT05196984","Gamma Frequency Stimulation in Individuals With Down Syndrome","Acute Exposure of Individuals With Down Syndrome to Gamma Frequency Stimulation","Inclusion Criteria:\n\n* Subject is between the ages of 25-65\n* Subject must have a clinically confirmed diagnosis of Down Syndrome (karyotypes optional). Individuals with mosaic Down syndrome will be excluded.\n* Subject or their legal guardian is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Subject will be medically stable with consistent medication over the previous 3 months.\n\nExclusion Criteria:\n\n* Subjects has history of a dual diagnosis Down Syndrome and Autism\n* Subjects with has history of seizure or epilepsy within the past 24 months.\n* Subjects with a new diagnosis of Attention-deficit\u002Fhyperactivity disorder (ADHD) (\\\u003C 6 months) or untreated ADHD\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have a known history a stroke within the past 24 months.\n* Subjects with a known history of migraine headache.\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Active treatment with one or more psychiatric agent (e.g. antidepressants, antipsychotics, etc).\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound and uncorrected hearing or visual impairment.\n* Subjects who are pregnant (self-report).","25 Years","65 Years",{"count":137,"type":21},60,[24],"Down Syndrome (DS) is characterized by an additional copy of chromosome 21, which also increases risk of Alzheimer's Disease (AD). The investigators' lab found a non-invasive way to remove toxic proteins from the brain in AD mouse models. Remarkably, treated mice also have improved memory on behavioral testing. The investigators then translated this non-invasive method, which uses light and sound to stimulate the brain, to be used in mild Alzheimer's patients and cognitively normal adults. The investigators have also translated this research into a vibrating speaker device to study tactile vibration to stimulate the brain as well. For the present study, 30 participants with Down Syndrome and 30 cognitively normal adult controls will be recruited, and the investigators will assess their brain waves with electroencephalogram (EEG) during light, sound, and tactile stimulation. The investigators will also test for safety, feasibility, and cognitive performance before and after a 30-60 minute session of light and sound stimulation to optimize the stimulation devices for use in the DS population.",[141],"Down Syndrome",[141,143,115,116,118,117],"Alzheimer Disease",{"date":121,"type":37},{"date":146,"type":37},"2021-12-06",{"date":148,"type":21},"2026-12-31",{"name":43,"class":44},{"id":151,"slug":152,"hasResults":11,"nctId":153,"briefTitle":154,"officialTitle":155,"acronym":156,"eligibilityCriteria":157,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":80,"enrollmentInfo":158,"targetDuration":4,"studyType":22,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":45},"100631149","phase-2-brain-effects-of-gamma-frequency-sensory-stimulation-40hz-light-sound-and-other-devices-100631149","NCT07496918","Brain Effects of Gamma Frequency Sensory Stimulation (40Hz Light, Sound and Other Devices)","Pilot Study to Evaluate Feasibility of Sensory Stimulation With Gamma Frequency Entrainment","GENUS","Inclusion Criteria:\n\n* Have adequate visual and auditory acuity for visual and auditory stimulation to allow for neuropsychological testing.\n* Be able to comply with neuropsychological testing and other study procedures in opinion of site PI.\n\nExclusion Criteria: Participants will be screened for the following exclusion criteria including if they\n\n* History of seizure or medical diagnosis of epilepsy.\n* Have MRI contraindications, such as presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin, or body.\n* Under the discretion of the site investigator, the site investigator feels the subject cannot complete sufficient key study procedures. Exceptions to these guidelines may be considered on a case-by-case basis at the discretion of the Project Director.",{"count":159,"type":21},150,[161],"PHASE2","Despite the huge healthcare and economic impact of AD, there is still no disease modifying therapeutics available. In fact, the available therapeutics show low efficacy at best in the treatment of cognitive impairment in dementia. Development of a non-invasive medical device that is effective in slowing cognitive impairment is not only revolutionary but also possibly cost- effective. In this study, participants will come to MIT for a 1-day visit and the investigators will evaluate the effects of GENUS in cognitively normal, healthy adults. Investigators will use Electroencephalogram (EEG), Magnetoencephalography (MEG), magnetic resonance imaging (MRI), neuropsychological testing, and blood sampling in subsets of participants to evaluate for biological effects and safety of GENUS stimulation.",[164,143],"Cognitively Healthy People","2026-03-24",{"date":167,"type":37},"2026-03-27",{"date":169,"type":37},"2018-02-20",{"date":171,"type":21},"2027-01-30",{"name":43,"class":44},{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":15,"sex":16,"minAge":135,"maxAge":80,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":181,"briefSummary":182,"conditions":183,"keywords":189,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":192,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":45},"100489597","chronic-treatment-of-alzheimers-disease-by-gamma-light-and-sound-therapy-100489597","NCT05655195","Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\nSubjects may be enrolled into the study if they meet all of the following criteria:\n\n* Subject is between the ages of 65 - 100.\n* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.\n* Subject is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.\n\nExclusion Criteria:\n\nSubjects who meet any of the following conditions will not be enrolled in the study:\n\n* Subjects who do not have healthcare.\n* Subjects who are currently taking amyloid reducing therapy.\n* Subjects who have \\> 4 cerebral microbleeds or 1 macrobleed in their brain\n* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).\n* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments\n* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with history of seizure or epilepsy\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Subjects with untreated or unstable depression\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have had a stroke within the past 24 months.\n* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)\n* Subjects diagnosed with migraine headache.\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound hearing or visual impairment.\n* Subjects who have a life expectancy of less than 2 years.\n* Subjects who are pregnant.\n* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.",{"count":137,"type":21},[24],"Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.",[143,184,185,186,187,188],"Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Alzheimer's Disease (Incl Subtypes)","Alzheimer's","Alzheimer's Disease",[187,190,191,116,117],"Alzheimer","Alzheimer's disease",{"date":119,"type":37},{"date":194,"type":37},"2022-12-14",{"date":196,"type":21},"2026-09-01",{"name":43,"class":44},{"id":199,"slug":200,"hasResults":11,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":204,"eligibilityCriteria":205,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":135,"enrollmentInfo":206,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":45},"100619272","gamma-light-and-sound-stimulation-in-schizophrenia-100619272","NCT07342465","Gamma Light and Sound Stimulation in Schizophrenia","Safety, Feasibility, and Preliminary Efficacy of Non-invasive Gamma Neuromodulation in Individuals With Schizophrenia Spectrum Disorders","Schizophrenia","Inclusion Criteria:\n\n1. Between 18-65 years of age.\n2. A diagnosis of schizophrenia or schizoaffective disorder\n3. No medication is an absolute exclusion. Medications will be reviewed by the responsible MD and a decision about inclusion will be made based on the following: the patient's past medical history, drug dose, history of recent medication changes or duration of treatment, and combination with other CNS (central nervous system) active drugs.\n4. The subject is willing to sign the informed consent document.\n5. If the subject is deemed not to have the capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n\nExclusion Criteria:\n\n1. Subjects who do not have healthcare\n2. MRI contraindications such as the presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments, or foreign objects in the eyes, skin or body.\n3. High myopia \\\u003C -7 diopters, or untreated cataracts that affect vision.\n4. Clinical conditions:\n\n   1. History of seizure or medical diagnosis of epilepsy.\n   2. ECT history \\> 6 months\n   3. Female subjects who are pregnant or currently breastfeeding.\n   4. Longstanding premorbid history (i.e., longer than 10 years) of alcohol or substance abuse with continuous abuse up to and including the time that the symptoms leading to clinical presentation developed.\n   5. Significant neurological or medical disorders that may produce cognitive impairment.\n   6. Profound hearing or visual impairment.\n   7. Eye surgery in the last 3 months or are scheduled to have eye surgery in the next 3 months (during the study)",{"count":20,"type":21},[24],"Schizophrenia (SZ) is a severe neuropsychiatric disorder impacting over 20 million people globally, causing significant personal and societal burdens, particularly due to cognitive deficits and negative symptoms inadequately treated by current therapies. To address this gap, investigators propose using Gamma Entrainment Using Sensory Stimulation (GENUS), a novel, home-based treatment involving synchronized 40 Hz light-and-sound stimulation aimed at improving neural synchrony, cognition, and SZ symptoms. This innovative approach leverages advanced neurostimulation, biological, and neuroimaging methods to directly target gamma dysfunction, fulfilling an urgent need for effective and accessible at-home therapies.\n\nThe goal of this clinical trial is to learn about the safety and feasibility of gamma stimulation using light and sound. It will also learn if gamma stimulation using light and sound works to treat clinical symptoms and cognitive impairments in schizophrenia. The main questions it aims to answer are:\n\n1. Is gamma stimulation safe for patients with schizophrenia spectrum disorders?\n2. Does gamma stimulation alleviate clinical symptoms and cognitive impairments in schizophrenia patients?\n\nParticipants will:\n\n1. Have an acute 1-hour stimulation at MIT.\n2. Come for a one-day visit to MIT for stimulation, neuroimaging, clinical, and cognitive evaluations.",[210],"Schizophrenia Spectrum Disorders",[212,213,214,156],"schizophrenia","sensory stimulation","gamma stimulation","2026-01-23",{"date":217,"type":37},"2026-01-26",{"date":219,"type":21},"2026-04",{"date":221,"type":21},"2027-04",{"name":43,"class":44},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":230,"targetDuration":4,"studyType":22,"phases":232,"briefSummary":234,"conditions":235,"keywords":237,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":45},"100489126","phase-4-investigating-the-effects-of-cannabidiol-on-social-anxiety-disorder-100489126","NCT05649059","Investigating the Effects of Cannabidiol on Social Anxiety Disorder","CAN-SAD","Inclusion Criteria:\n\n* Ability and willingness to provide written informed consent.\n* Sufficiently fluent in English to participate in the trial.\n* Between 18-55 years of age (inclusive).\n* Right-hand dominant.\n* Current medications are stable for past 30 days (no changes to dose or frequency).\n* Negative result on pregnancy test (if female).\n* Negative result on urine drug screening.\n* Liebowitz Social Anxiety Scale (LSAS ≥ 60).\n\nExclusion Criteria:\n\n* History of bipolar disorder, schizophrenia, psychosis, delusional disorders.\n* History of eating disorder within past 6 months.\n* History of any traumatic brain injury.\n* Currently diagnosed with diabetes mellitus.\n* Presence of severe medical illness that would prevent completion of study procedures.\n* Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).\n* History of substance use disorder within past 6 months (other than nicotine and caffeine).\n* Use of any cannabis-containing products in past 30 days (CBD or THC).\n* Use of benzodiazepines in past 2 weeks.\n* Use of alpha- or beta-blockers in past week.\n* History of claustrophobia.\n* Contraindications for MRI (e.g.; shrapnel).\n* Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures.\n* Use of concomitant medication that has a strong interaction with CBD.\n* History of liver disease.\n* History of hypersensitivity to cannabinoids.\n* History of hypersensitivity to sesame seed oil.\n* Currently breastfeeding (if female).",{"count":231,"type":21},50,[233],"PHASE4","The purpose of this study is to test whether a single-dose of Epidiolex (cannabidiol) is associated with reduced psychological, physiological, and neuroimaging measures of anxiety in people diagnosed with social anxiety disorder (SAD).",[236],"Phobia, Social",[238,239,240],"Social Anxiety Disorder","Cannabidiol","fMRI","2025-11-25",{"date":243,"type":37},"2025-12-03",{"date":245,"type":37},"2025-07-10",{"date":247,"type":21},"2026-09",{"name":43,"class":44},{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":15,"sex":16,"minAge":52,"maxAge":18,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":45},"100484695","investigating-the-effects-of-social-stress-on-brain-imaging-100484695","NCT05591404","Investigating the Effects of Social Stress on Brain Imaging","SSBI","Inclusion Criteria:\n\n* Ability and willingness to provide written informed consent.\n* Sufficiently fluent in English to participate in the trial.\n* Between 18-55 years of age (inclusive).\n* Right-hand dominant.\n* Current medications are stable for past 30 days (no changes to dose or frequency).\n* Negative result on pregnancy test (if female).\n* Negative result on urine drug screening.\n* Liebowitz Social Anxiety Scale (LSAS \\\u003C30).\n\nExclusion Criteria:\n\n* History of bipolar disorder, schizophrenia, psychosis, delusional disorders.\n* History of eating disorder within past 6 months.\n* History of any traumatic brain injury.\n* Currently diagnosed with diabetes mellitus.\n* Presence of severe medical illness that would prevent completion of study procedures.\n* Presence of significant neurological illness or cognitive dysfunction (e.g.; seizures, dementia).\n* History of substance use disorder within past 6 months (other than nicotine and caffeine).\n* Use of any cannabis-containing products in past 30 days (CBD or THC).\n* Use of benzodiazepines in past 2 weeks.\n* Use of alpha- or beta-blockers in the past week.\n* History of claustrophobia.\n* Contraindications for MRI (e.g.; shrapnel).\n* Presence of any other medical condition that, in the investigator's opinion, may interfere with the study procedures.",{"count":231,"type":21},[24],"The purpose of this study is to examine whether experiencing a social stressor prior to the collection of neuroimaging measures is associated with differences in brain activation in healthy participants.",[260],"Social Stress",[260,240],{"date":243,"type":37},{"date":264,"type":37},"2025-11-17",{"date":266,"type":21},"2026-11",{"name":43,"class":44},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":4,"eligibilityCriteria":273,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":274,"targetDuration":4,"studyType":22,"phases":275,"briefSummary":276,"conditions":277,"keywords":279,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":45},"100608696","evaluation-of-a-neural-controlled-powered-prosthesis-across-diverse-real-world-tasks-100608696","NCT07204912","Evaluation of a Neural-Controlled Powered Prosthesis Across Diverse Real-World Tasks","Inclusion Criteria:\n\n* Male or Female age 18-70.\n* The patient must have a unilateral transfemoral amputation .\n* The patient must have the ability to ambulate at variable cadence (an expected lower extremity prosthesis functional level of K3 or above).\n* The patient must have adequate socket to support the device.\n\nExclusion Criteria:\n\n* Women who are pregnant.\n* Severe co morbidity, atypical skeletal anatomy, or poor general physical\u002Fmental health that, in the opinion of the Investigator, will not allow the subject to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectancy, vulnerable patient population, BMI \\>40, etc.).",{"count":55,"type":21},[24],"The purpose of this study is to evaluate the performance and adaptability of a neural-controlled powered knee or ankle prosthesis across diverse real-world mobility tasks. This research aims to assess how compare the sense of embodiment with the device, symmetry, and stability of a person with an lower-extremity amputation walking with a bionic prosthesis and their prescribed prosthesis. Findings from this study will inform future developments in bionic prosthesis design with optimal integration with the human body, with the goal of improving prosthetic integration into daily life.",[278],"Transfemoral Amputation",[278,280,281],"Bionic Prosthesis","Knee Prosthesis","2025-09-24",{"date":284,"type":37},"2025-10-02",{"date":286,"type":37},"2025-05-31",{"date":288,"type":21},"2028-05-31",{"name":43,"class":44},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":297,"targetDuration":4,"studyType":22,"phases":299,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":305,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":45},"100571842","wellness-program-outreach-and-effectiveness-100571842","NCT06725511","Wellness Program Outreach and Effectiveness","Wellness Program Outreach and Effectiveness: A Randomized Controlled Trial","Inclusion Criteria:\n\n1. Provided informed consent.\n2. Those who are eligible for the Pack Health program:\n\n   * Employees\u002Fspouses\u002Fdomestic partners over the age of 18\n   * Metabolic syndrome defined as results indicating 3 or more of the following risk factors:\n\n     * High waist circumference (\\>35 inches for women and \\>40 inches for men)\n     * High triglycerides (≥150 mg\u002Fdl)\n     * Low HDL cholesterol (\\\u003C50 mg\u002Fdl for women and \\\u003C40 mg\u002Fdl for men)\n     * High Blood Pressure (≥130\u002F85)\n     * High Fasting Glucose (≥100 mg\u002Fdl)\n\nExclusion Criteria:\n\n* 1\\. Anyone under the age of 21. They will not be part of the study and will receive messages as if they were in the control group.\n\n  2\\. Anyone observed in claims data with a historical diagnosis of:\n  * Anorexia nervosa\n  * Bulimia nervosa\n  * Binge-eating disorder\n  * Body dysmorphic disorder\n  * Major depression\n  * Post-traumatic stress disorder (PTSD)\n  * Severe anxiety disorder",{"count":298,"type":21},2000,[24],"The investigators will conduct a randomized controlled trial to evaluate the impact of an outreach campaign designed to increase engagement with Pack Health, a Quest Diagnostics wellness program providing individual health coaching for weight management and diabetes prevention. While employee wellness and disease-management programs have the potential to improve wellbeing and reduce healthcare costs, their effectiveness is often undermined by low engagement and selection bias in participant comparisons. This study will test whether an outreach approach that auto-enrolls eligible individuals-employees and their spouses\u002Fdomestic partners-into the program, with the option to opt out, can increase engagement and improve health outcomes compared to the standard invitation-based approach.",[302],"Metabolic Syndrome",[302,304],"Workplace wellness","2024-12-04",{"date":307,"type":37},"2024-12-10",{"date":309,"type":37},"2024-10-02",{"date":311,"type":21},"2026-08-31",{"name":43,"class":44},""]